InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder Study

InflaRx NV (NASDAQ: IFRX) has announced new data Phase 2b SHINE study, evaluating vilobelimab (IFX-1) in moderate and severe Hurley Stage II and III hidradenitis suppurativa (HS), a chronic skin condition characterized by the formation of painful lumps under the skin typically in the armpit, groin and genitalia regions.
Updated data demonstrated dose-dependent suppression of elevated C5a levels. Within the high-dose treatment group (1200 mg q2w), C5a levels were suppressed to levels below normal median C5a levels of healthy humans at day four and week 16 upon initiation of treatment.
Vilobelimab is a monoclonal anti-human complement factor C5a antibody and inhibits the complement C5a receptor, which plays a key role in the inflammatory process.
Price Action: IFRX stock gained 3.6% at $6.01 in premarket trading on the last check Thursday.